Coronavirus / COVID

Investigators developed a hybrid protocol to search for potential drug candidates against the replication of SARS-CoV-2.

The global health agency provided current insights and advisories into 4 different variants observed during COVID-19 this year.

The newly published data show no patient given the two-dose mRNA vaccine has yet to report a case of severe COVID-19.

Though regulatory authorization has not been granted, the company intends to vaccinate up to 50 million people prior to the Lunar New Year.

The authorization recommends dosage intervals of between 4 and 12 weeks.

Nearly 20% of patients who survive hospitalization are readmitted within 60 days, researchers find.

A research team recently sought to address this knowledge gap by analyzing a sample of US patients with COVID-19 infections.

Trial to enroll up to 30000 volunteers across approximately 115 sites in the US and Mexico.

With the public beginning to get vaccinated, CDC published information for people in some medical categories and considerations on severe allergic reactions.

Between March 1 and July 31, there were 76088 deaths among Americans aged 25 to 44, amounting to 11899 (18.5%) more than expected during that timeframe, new research shows.

The new COVID-19 variant, B.1.1.7, continues to make its way around Europe and the world with new cases.

A new study from Italy provides evidence that new mothers with COVID-19 can safely breastfeed and stay together in the same room with their newborns after delivery if they follow safety precautions.

Vaccine manufacturer Valneva recently announced it was initiating a phase 1/2 trial in the United Kingdom.

Anti-COVID-19 nanobodies may potentially be effective at preventing and diagnosing infections.

Phase 3 trial data shows experimental monoclonal antibody not to be efficacious.

While ACE2 expression has been reported in the human brain, the cell-specific expression pattern of ACE2 is unknown.

The agreement could mean upwards of 70 million more doses for eligible patients in mid-2021.

Characterizing SARS-CoV-2 interactions can improve understanding of viral RNA functions and the host innate immune response.

Regional and national decision-making can be informed by the online model, called the COVID-19 Pool Tool.

Though research is pending, the CEO used simple science to explain why the mRNA vaccine may still prevent from the UK variant.

The study helps to illuminate how spike proteins initiate infections.

Countries across Europe are reinstating travel bans and lockdowns to combat virus.

A new case series report highlights the unique circumstances of infant illness associated with COVID-19.

New data suggests informed, practical pooled testing could improve both public health response and clinical assessment of the pandemic.

Healthcare providers may want to consider these risks when determining which COVID-19 patients could benefit the most from the new monoclonal antibody therapies.